The article discusses the reuse of medications to treat diseases for which they were not originally designed. Topics include the use of the drug chlorpromazine to treat schizophrenia, the testing and approval of drugs by the U.S. Food and Drugs Administration (FDA), and researcher access to information from pharmaceutical companies.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados